Date: 2016-04-11
Type of information: Nomination
Compound:
Company: Seventure Partners (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 11, 2016, Seventure Partners, one of Europe’s leaders in financing innovation, announced that it has furthered strengthened its Life Sciences team with two new appointments; Professor Denise Kelly joins as an Investment Advisor whilst Oxana Kukhaneva has been appointed Venture Partner. Ms. Kukhaneva joins Seventure from Inventages Venture Capital, where she was Investment Manager of the investment team. Oxana brings over 12 years’ experience in private equity investment in venture and growth in healthcare, nutrition and consumer goods. Born and raised in Russia, she started her career in project finance and business development, working for a software start-up company. Oxana holds a BA in International Relations and Affairs and a BS in Economics from the Moscow State Institute of International Relations MFA Russia MGIMO, as well as an MA and MBA from the International Institute for Management Development in Switzerland. Professor Kelly joins Seventure from the Rowett Institute, University of Aberdeen where she was a Professor of Immunology and Microbiology for over 25 years. In tandem, she held the roles of CEO and CSO at GT Biologics Ltd, a spin-out of the Rowett Institute, from 2008-2015. Professor Kelly holds a BSc and PhD from the Queen’s University, Belfast and gained her Emeritus Professorship from the University of Aberdeen. Her significant experience in gut microbiology and immunology brings key expertise to Seventure, where her main focus will be on microbiome investments.
Financial terms:
Latest news:
